NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the filing of two new patent applications that further expand the Company’s intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis. The first newly filed patent covers a combination therapy pairing tapinarof with a class of drugs clinically proven in psoriasis and atopic dermatitis ...

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that it has completed initial signature mapping of its asset portfolio against Sarborg Limited’s recently curated rare disease database, identifying multiple high-potential opportunities across a range of rare and underserved indications. The analysis, conducted using Sarborg’s proprietary AI Signature Agent platform, evaluated CDT’s portfolio of assets, incl ...

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that all proposals put forth at the Special Meeting of Stockholders of CDT, held on Tuesday, March 17, 2026, were duly passed by the stockholders. “Following the successful passing of all the proposals at yesterday’s Special Meeting, CDT Equity continues to transform through its $123M investment in Sarborg, the continued expansion of its IP portfolio, potentia ...

Core Insights - CDT Equity Inc. has announced a collaboration with Sarborg Limited to utilize an expanded rare disease signature database for mapping its asset portfolio [3][5] - Sarborg has curated a database of approximately 1,700 rare disease signatures, enhancing its existing library of over 1,600 conditions, which will facilitate rapid analysis of disease relationships and therapeutic opportunities [2][3] Company Overview - CDT Equity Inc. is a data-driven biopharmaceutical development company focused on advancing high-potential therapeutic assets through scientific innovation and strategic partnerships [5] - The company aims to create shareholder value through licensing, strategic mergers and acquisitions, and positioning itself as a platform for transformative innovation [5] Collaboration Details - The collaboration with Sarborg will allow CDT to maximize its intellectual property position and explore commercialization opportunities through external partnerships [3] - CDT holds a 20% equity stake in Sarborg and continues to leverage its cross-industry signature intelligence platform [3]

Core Viewpoint - CDT Equity Inc. acknowledges the filing of a U.S. provisional patent application by Sarborg Limited for its AI Signature Agent, viewing it as a significant step in enhancing Sarborg's intellectual property position and supporting its long-term growth potential [1][3]. Group 1: Patent Filing Details - Sarborg filed a provisional patent application with the United States Patent and Trademark Office on February 12, 2026, assigned United States Patent Application No. 63/981,801 [2]. - The application pertains to Sarborg's Signature Agent architecture and its methodology for encoding and analyzing biological, chemical, and industrial signatures to produce intelligence-driven outputs [2]. Group 2: Company Perspective - As a 20% shareholder, CDT views the patent filing as a crucial milestone in the development and protection of Sarborg's proprietary technology [3]. - The advancement of Sarborg's intellectual property is believed to support the scalability of its Signature Agent across various sectors, enhancing its long-term growth profile [3]. Group 3: Company Overview - CDT Equity Inc. is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships [4]. - The company aims to create shareholder value through licensing, strategic mergers and acquisitions, and positioning itself as a platform for transformative innovation [4].

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 04, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) advances multiple initiatives designed to enhance shareholder value and expand its strategic footprint. The Company continues to actively develop and expand its pharmaceutical asset portfolio, including solid-form and cocrystal development programs, alongside its licensed clinical assets AZD1656, AZD5658 and AZD5904 under its agreement with AstraZeneca. CDT remains engaged in ...

Core Viewpoint - CDT Equity Inc. recognizes the strategic expansion of Sarborg Limited's AI Signature Agent platform into bacteria and agrochemicals as a significant development that enhances its market potential and growth profile [2][4]. Company Overview - CDT holds a 20% equity stake in Sarborg Limited, which is a key player in the AI signature intelligence sector [2]. - The company focuses on leveraging artificial intelligence and strategic partnerships to advance high-potential therapeutic assets [6]. Industry Development - Sarborg has successfully curated approximately 4,500 agrochemical signatures and around 1,600 bacterial signatures, indicating the scalability of its platform beyond pharmaceuticals [3]. - The expansion into new sectors demonstrates the versatility and strength of Sarborg's sector-agnostic architecture [4]. Strategic Implications - The expansion is viewed as a meaningful opportunity for CDT to provide public market investors with exposure to Sarborg's ongoing development and growth [4]. - CDT plans to continue monitoring and supporting Sarborg as it enhances its signature libraries and positions itself as a multi-sector AI signature intelligence platform [4].

Core Viewpoint - CDT Equity Inc. has announced a strategic transaction to acquire a 20% equity stake in Sarborg Limited, enhancing collaboration and growth opportunities for both companies [1][3][4]. Group 1: Strategic Transaction - The acquisition formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's AI capabilities [2][3]. - The total consideration for the acquisition is $115 million, to be settled through the issuance of 598,005 new common stock in CDT and 109,978,918 pre-funded warrants, pending shareholder approval [5]. Group 2: Business Synergies - Sarborg's business focuses on using biological, chemical, and industrial signatures as a universal data language to identify and generate high-value opportunities, which aligns with CDT's focus on solid-form development [2][3]. - The transaction provides CDT shareholders with exposure to Sarborg's growth beyond pharmaceuticals, allowing for broader participation in sectors where signature analysis can be applied [4]. Group 3: Leadership Perspective - Dr. Andrew Regan, CEO of CDT, emphasized that acquiring a stake in Sarborg strengthens their relationship and aligns with a business whose innovative approach is complementary to CDT's own [5].

Core Viewpoint - CDT Equity Inc. has engaged NJS Foresight Bio-Advisory to enhance its out-licensing opportunities for its solid-form patent portfolio, aiming to expand commercial reach and accelerate licensing transactions [1][4]. Group 1: Company Strategy and Engagement - The engagement with NJS Foresight Bio-Advisory is focused on identifying and supporting out-licensing opportunities for selected assets within CDT's solid-form patent portfolio [1]. - NJS Foresight Bio-Advisory has over 20 years of experience in out-licensing and has successfully completed numerous agreements in the biotechnology and pharmaceutical sectors [2]. - Dr. Nicholas J. Sarlis, the principal of NJS Foresight, has extensive expertise in clinical and pharmaceutical development, having led teams in both early and late-stage programs and participated in over thirty clinical studies [2]. Group 2: Solid-Form Patent Portfolio - CDT's solid-form patent portfolio includes cocrystals and salts that provide enhanced physicochemical properties, such as improved solubility and bioavailability, with up to twenty years of patent protection [3]. - The company is actively exploring opportunities where marketed products face significant patent cliffs, leveraging its differentiated solid-forms of active pharmaceutical ingredients [4]. Group 3: Market Environment and Future Outlook - Industry data indicates a renewed investment activity in biopharma, driven by patent expirations, strategic consolidation, and the adoption of AI technologies, creating a favorable environment for solid-form innovation and out-licensing [4]. - CDT's CEO, Dr. Andrew Regan, emphasized the strong potential for solid-form assets to support lifecycle management strategies across the sector [5]. Group 4: Company Overview - CDT Equity Inc. is a biopharmaceutical development company focused on enhancing high-potential therapeutic assets through scientific innovation and strategic partnerships [6]. - The company has implemented a cryptocurrency treasury reserve strategy, initially focused on Bitcoin, to diversify capital allocation and strengthen its financial position [6].

Core Viewpoint - CDT Environmental Technology Investment Holdings Limited held its annual general meeting (AGM) on November 26, 2025, where all resolutions were passed by shareholders, including a significant share consolidation plan [1][2]. Shareholder Resolutions - The AGM approved a consolidation of every twenty-five (25) existing Class A ordinary shares of US$0.0025 par value into one (1) Class A ordinary share of US$0.0625 par value [2]. - Similarly, every twenty-five (25) existing Class B ordinary shares of US$0.0025 par value will be consolidated into one (1) Class B ordinary share of US$0.0625 par value [2]. - The authorized share capital will be adjusted to US$250,000, divided into 3,760,000 Class A ordinary shares and 240,000 Class B ordinary shares [2]. - Fractional entitlements resulting from the share consolidation will not be issued but rounded up to the next whole number [2]. - The Board is authorized to determine the effective date of the share consolidation and make necessary changes to the authorized share capital [2]. Board Appointments - Mr. Ling Kai was appointed as an executive director of the Company with immediate effect [3]. - Mr. Chen Xi was appointed as an independent director of the Company with immediate effect [3]. Voting Results - The independent inspector of election certified that 6,166,191 shares were voted, representing approximately 50.03% of CDT's outstanding shares as of the record date [4]. - The share consolidation will only take place if the Board determines it is in the best interest of the Company, with the discretion to effect the consolidation expiring on the first anniversary of the AGM [5]. Company Overview - CDT is a leading provider of waste treatment systems and services in China, focusing on sustainable development through innovative solutions [6]. - The Company designs, develops, manufactures, sells, installs, operates, and maintains sewage treatment systems, having completed over 150 plants across China [7]. - CDT aims to help customers achieve critical infrastructure objectives while promoting positive changes in environmental protection technology [7].